Overview
Zentalis is a clinical oncology innovator developing a treatment approach for ovarian cancer and multiple tumor types. Leveraging therapeutics development and biomarker expertise, Zentalis is advancing monotherapy and combination studies of its investigational first-in-class WEE1 inhibitor, azenosertib. Focused on translating WEE1 science into clinical practice, we aim to equip physicians with a targeted, non-chemo, orally available medicine that enhances treatment experience, choice, and outcomes. Our mission: to unburden cancer patients with more convenience and care.
Position Summary:
The Associate Director Scientific Communications will be a key member of the Medical Affairs team. This key role will play a pivotal role in translating complex data into clear, credible, and impactful scientific evidence and narratives that shape how Zentalis treatment approach for ovarian cancer and multiple tumor types is understood and applied across the global medical community. Operating at the intersection of strategy and execution, this role partners closely with cross-functional colleagues and external experts to deliver high‑impact publications and scientific communications that advance both patient care and scientific dialogue. This is a unique opportunity to join a highly collaborative, mission‑driven team known for scientific excellence, thoughtful partnership, and getting meaningful data to the audiences who need it most.
Essential Duties and Responsibilities:
- Contribute to the development of global strategic publication and scientific communications plans in alignment with the overall corporate strategy
- Manage the planning and execution of publication tactics (manuscripts, abstracts, posters, oral presentations etc.) in accordance with GPP3, ICMJE, and Zentalis policies
- Ensure the development and dissemination of scientific, clinical, and health-related information to healthcare professionals, patients, payers, regulators, and other stakeholders (Medical Information/MedComms)
- Facilitate and operationalize the publication review process at Zentalis
- Facilitate discussions/decisions at regular publication team meetings related to publication planning and execution
- Develop and/or update scientific platforms
- Manage and execute the development of scientific communication tactics, FAQs, medical tools, and congress materials
- Partner with internal and external SMEs to develop credible, accurate, and impactful scientific content
- Ensure materials progress efficiently through medical and publication review committees
- Manage scientific communication and publication vendors, as well as electronic publication management systems
- Identify opportunities to proactively address clinical and scientific knowledge gaps
- Build and maintain disease‑area expertise through continuous review of the scientific literature
- Development of scientific training tactics (eg, internal training MSL decks, tools, FAQs).
Knowledge/Skills/Abilities Required:
- Advanced degree with 5-7+ yrs. experience in scientific communication, training, publications planning and development in an agency or pharmaceutical environment or applicable experience working in pharmaceutical environment with transferable skill set.
- Prior hands-on experience in medical information & communications for a pharmaceutical company is required.
- Demonstrated ability to work with cross-functional teams and/or agencies to develop abstracts, posters, oral presentations, manuscripts, slide decks, and content for scientific and educational programs
- Strong project management skills and leadership poise to negotiate and facilitate alignment amongst internal and external stakeholders (KOLs, authors, cross-functional teams)
- Proven ability to be well organized, multi-task, and manage vendors, timelines, and competing priorities in a fast‑paced, deadline-driven environment
- Excellent and effective interpersonal and communication skills
- Strong understanding of publication compliance standards (GPP3, ICMJE, FDA/OIG guidance, MALR)
- Willingness to travel (U.S. and international) ~20%
